ctDNA-Guided Therapy in Stage II Colon Cancer | NEJM

PD-1 Blockade in Locally Advanced Rectal Cancer | NEJMПодробнее

Colon CancerПодробнее

DYNAMIC: ctDNA guiding adjuvant chemotherapy in stage II colon cancerПодробнее

Highlights on adjuvant chemotherapy of stage II colon cancer: The DYNAMIC TrialПодробнее

Blood based Colon Cancer Screening - NEJM papers - ECLIPSE - GuardantПодробнее

Colonoscopy Screening for Colorectal Cancer | NEJMПодробнее

Can we refine the selection for adjuvant treatment in stage II colon cancer?Подробнее

Journal Club - DNA shed from colon cancers into bloodstream guides chemotherapy post surgeryПодробнее

Using ctDNA to Guide Adjuvant Therapy in Stage II Colorectal CancerПодробнее

New study of colonoscopy screeningПодробнее

Polypill in Secondary CV Prevention | NEJMПодробнее

Colon Cancer | 2022 OneOncology ConferenceПодробнее

The emerging role of ctDNA in cancer diagnosticsПодробнее

2021 West Oncology | Gastrointestinal Cancers | ctDNA Analysis in Colorectal CancerПодробнее

Illumina Oncology | ctDNA-guided treatment in colorectal cancerПодробнее

In Defense of Colonoscopy – A Commentary on the NEJM Colorectal Cancer ScreeningПодробнее

NRG-GI005: ctDNA predicts adjuvant chemo in stage II colon cancerПодробнее

DYNAMIC - Circulating Tumor DNA to decide Adjuvant Chemo in Stage II Colon Cancer | LEVEL - HARDПодробнее

Journal Club - Locally advanced rectal cancer highly sensitive to single-agent PD-1 blockadeПодробнее